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Abstract
Background: Both fish oil and montelukast have been shown to reduce the severity of exercise-induced
bronchoconstriction (EIB). The purpose of this study was to compare the effects of fish oil and montelukast, alone and
in combination, on airway inflammation and bronchoconstriction induced by eucapnic voluntary hyperpnea (EVH) in
asthmatics.
Methods: In this model of EIB, twenty asthmatic subjects with documented hyperpnea-induced bronchoconstriction (HIB)
entered a randomized double-blind trial. All subjects entered on their usual diet (pre-treatment, n=20) and then were
randomly assigned to receive either one active 10 mg montelukast tablet and 10 placebo fish oil capsules (n=10) or one
placebo montelukast tablet and 10 active fish oil capsules totaling 3.2 g EPA and 2.0 g DHA (n=10) taken daily for 3-wk.
Thereafter, all subjects (combination treatment; n=20) underwent another 3-wk treatment period consisting of a 10 mg
active montelukast tablet or 10 active fish oil capsules taken daily.
Results: While HIB was significantly inhibited (p,0.05) by montelukast, fish oil and combination treatment compared to
pre-treatment, there was no significant difference (p.0.017) between treatment groups; percent fall in forced expiratory
volume in 1-sec was 218.462.1%, 29.362.8%, 211.662.8% and 210.861.7% on usual diet (pre-treatment), fish oil,
montelukast and combination treatment respectively. All three treatments were associated with a significant reduction
(p,0.05) in FENO, exhaled breathe condensate pH and cysteinyl-leukotrienes, while the fish oil and combination treatment
significantly reduced (p,0.05) urinary 9a,1 1 b-prostaglandin F2 after EVH compared to the usual diet; however, there was
no significant difference (p.0.017) in these biomarkers between treatments.
Conclusion: While fish oil and montelukast are both effective in attenuating airway inflammation and HIB, combining fish oil
with montelukast did not confer a greater protective effect than either intervention alone. Fish oil supplementation should
be considered as an alternative treatment for EIB.
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Introduction
Exercise-induced bronchoconstriction (EIB) and exercise-in-
duced asthma are terms used interchangeably that describe a
transient narrowing of the airways during or following exercise [1]
that can occur in patients with asthma [2] and elite athletes [3].
The mechanisms responsible for EIB likely involve multiple
mechanistic pathways, however it is generally accepted that
exercise or dry air hyperpnea play an important role as an
initiating stimulus through airway surface effects of water loss,
which include mucosal cooling and dehydration [1]. This transient
dehydration causes an increase in airway surface liquid osmolarity
which activates histamine, neuropeptides, and arachidonic acid
metabolites such as cysteinyl (Cyst)- leukotrienes [(LTs) e.g., LTC4,
D4 and E4)] and prostaglandins, from resident airway cells,
resulting in bronchial smooth muscle contraction and subsequent
airway obstruction [4].
The Cyst-LTs, produced predominantly by mast cells and
eosinophils [5], are the most potent constrictors of human airway
smooth muscle in vitro and in vivo [5,6], and have been implicated
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subsequently in airway remodeling [7]. There are distinct
approaches to reducing the actions of Cyst-LTs: inhibition of
biosynthesis (e.g., inhibitors of 5-lipoxygenase (5-LO) and 5-LO-
activating protein) or blockade of Cyst-LT1 receptors using
leukotriene receptor antagonists [e.g., montelukast sodium (Singu-
lair H) and zafirlukast] [8]. Both these drugs inhibit the maximum
bronchonstrictor response to exercise or dry air hyperpnea by 30
to 70% [9,10,11,12,13,14], which indicates that other mediators
may play a role in the pathogenesis of EIB [10]. Whilst both drugs
have been shown to reduce EIB severity, only montelukast has
been approved by the US Food and Drug Administration for this
purpose [15].
Although the treatment of EIB almost exclusively involves
pharmacotherapy, there is now convincing evidence that dietary
modification has the potential to reduce the severity of this
condition [16]. While the clinical data on the effect of fish oil
supplementation in asthma has been equivocal [17] supplementing
the diet with fish oil, rich in omega-3 (n-3) polyunsaturated fatty
acids (PUFA), such as eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA), in individuals with EIB has yielded
promising results [18,19]. Eicosapentaenoic acid can compete with
arachidonic acid, as a substrate for cyclooxygenase (COX)-2 and
5-lipoxygenase (5-LO) enzymes and be converted to less
inflammatory leukotrienes and prostanoids [20,21]. At present
the mechanism(s) underpinning the anti-inflammatory effects of
DHA are unclear, but may be related to altered gene transcription
and translation via direct or indirect actions on intracellular
signaling pathways [22,23].
Since the Cyst-LTs are, overall, the most potent pro-
inflammatory mediators causing EIB [24] an important question
is how dietary fish oil supplementation fits in with the available
armamentarium (e.g., Cyst-LT type 1 receptor antagonists) to
decrease the expression of Cyst-LTs, and whether fish oil
supplementation may be additive, or used in its own right to
block the bronchoconstrictor response. Therefore, the primary
aim of the present study was to evaluate the effects of fish oil
supplementation and a Cyst- LT1 receptor antagonist [montelu-
kast sodium (SingulairH), a commonly used medication to treat
EIB], alone and in combination, on airway inflammation and the
bronchoconstrictor response to dry air hyperpnea in individuals
with asthma.
It was hypothesized that both fish oil and montelukast would be
effective in attenuating hyperpnea-induced bronchoconstriction
(HIB) and airway inflammation, and that the two treatments
combined would infer even greater protection against HIB than
either intervention alone. Our findings showed that fish oil
supplementation and montelukast are both effective in moderating
airway inflammation and HIB in asthmatic individuals. However,
combining fish oil with montelukast did not confer a greater
protective effect than either intervention alone.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Subjects
The study was conducted between October 2008 and March
2009 in the United States. Twenty subjects aged 18 to 27 years old
withboth physician-diagnosed asthmaanddocumentedhyperpnea-
induced bronchoconstriction were recruited from a population of
university students and the local community. Subject characteristics
at baseline are presented in Table 1. All subjects had clinically
treated mild to moderate persistent asthma, with an resting forced
expiratory volume in 1-sec (FEV1)o f.65% predicted (Table 2),
and EIB as demonstrated by a greater than 10% drop in FEV1
following a eucapnic voluntary hyperventilation (EVH) challenge
[25]. A group of non-asthmatic (control) subjects was not included
in the present study, as it has been shown that fish oil
supplementation does not alter pulmonary function or inflamma-
tory mediator generation in this population [19].
Table 1. Subject (baseline) characteristics.
Characteristics (n=20)
Sex, n
Males 6
Females 14
Age, yr (range) 20.862.2 (18–27)
Height, m 1.7060.04
Weight, kg 72.4613.4
BMI, kg/m2 24.964.0
Morning peak flow, L/min 380.7682.7
Evening peak flow, L/min 393.1690.7
Values reported are mean 6 SEM.
doi:10.1371/journal.pone.0013487.t001
Table 2. Pre-hyperpnea (baseline) pulmonary function.
Treatment Period
Pre-treatment (n=20) Montelukast (n=10) Fish Oil (n=10) Combination Treatment (n=20)
FVC (L) 4.5160.22 4.3060.18 4.6460.43 4.6160.31
% predicted 105.063.3% 100.964.4% 106.665.7% 105.763.9%
FEV1 (L) 3.6760.19 3.3460.19 3.8160.31 3.6960.24
% predicted 100.864.2% 96.166.3% 102.565.6% 102.365.0%
FEF25–75% (L/min) 3.6760.27 3.0060.26 3.8260.38 3.7160.29
% predicted 90.666.3% 80.766.4% 100.368.8% 91.766.8%
Values reported are mean 6 SEM.
doi:10.1371/journal.pone.0013487.t002
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and intermittent wheezing following exercise, which was relieved
by bronchodilator therapy. No subjects who volunteered for the
study were currently taking any maintenance medications (e.g.,
corticosteroids and leukotriene modifiers) for asthma. Short acting
b2-agonists were discontinued 12 h prior to testing. Caffeine/
alcohol and physical exercise was not permitted 8 h and 12 h
respectively prior to the EVH challenge. Subjects were also
excluded if they had a history of taking fish oil supplements and
regularly consumed more than one fish meal per week. Subjects
were asked not to eat more than one fish meal per week during the
course of the study. Subjects were excluded if they were pregnant,
had a history of hyperlipidemia, hypertension, diabetes, bleeding
disorders, or delayed clotting time. The study was approved by the
Indiana University Institutional Review Board for Human
Subjects, and written informed consent for all subjects was
obtained prior to participation in the study. The study was
registered as a phase 1 clinical trial with clinical trials.gov (study #
NCT00676468).
Study Design
The study was conducted over the course of 8 weeks as a
matched (by gender), double-blind randomized controlled parallel
group trial over 3 weeks followed by a single group trial (both
groups combined) for a further 3 weeks. Each subject underwent a
2 –week run period preceding the start of the trial in which asthma
symptoms were recorded. Testing in the laboratory was conducted
following the run in period (usual diet) and at the conclusion of
each 3-week treatment period. All tests were conducted in the
human performance and exercise biochemistry laboratories at
Indiana University-Bloomington. An independent investigator
having no contact with the subjects and no involvement in data
collection or analysis used a computerized random number
generator (‘‘research randomizer’’ http://www.randomizer.org/
form.htm) to create the randomization sequence which was
stratified by sex with a 1:1 allocation using a fixed random block
size of two.
All subjects entered the study on their usual diet (phase 1) and
then randomly assigned to one of two groups matched by gender
(Figure S1). The two parallel treatment regimens (phase 2) consisted
of either one active montelukast sodium (SingulairH; Merck& Co.
Inc, Whitehouse Station, NJ) 10 mg tablet taken orally once daily
and 10 placebo fish oil capsules (Nordic Naturals, Watsonville,
CA) per day containing soybean oil (n=10) or one placebo
montelukast sodium tablet taken orally once daily and 10 active
fish oil capsules taken daily equaling a total of 3.2 g EPA and 2.0 g
DHA (n=10). Following phase 2, all subjects underwent another 3-
week treatment period consisting of an active montelukast sodium
10 mg tablet, taken orally once daily in the evening and 10 active
fish oil capsules taken daily (n=20) (phase 3). Both the active and
placebo fish oil capsules, and the active and placebo montelukast
tablets, were identical in size and appearance to each other.
A eucapnic voluntary hyperventilation (EVH) challenge (surro-
gate for an exercise challenge test) was performed at the end of
phase 1, 2 and 3 [26]. Pulmonary function was monitored pre-
EVH and post-EVH at 5, 10, 15, and 20 min. Exhaled nitric oxide
(FENO), a non-invasive measure of airway inflammation, was
measured pre-EVH and at 30 min post-EVH. Exhaled breath
condensate (EBC) was collected pre-EVH and post-EVH from 0–
10 min and analyzed for the presence of the Cyst-LTs and airway
pH. Urine samples were collected pre-EVH and 60 min post-
EVH for 9a,1 1 b-Prostaglanind F2 analysis. Subjects were asked to
record daily peak flow and symptom scores throughout the course
of the study. Food frequency questionnaires were administered at
the beginning of each testing session.
Eucapnic Voluntary Hyperventilation
The EVH protocol required subjects to breathe compressed dry
air (,3m gH 2O.L
21 air and 21%O2, 5%CO2, balance N2)a ta
predetermined rate of 85% of maximal voluntary ventilation
(estimated from 306the volume of resting FEV1) for 6 min [13].
Gas flowed from a cylinder to a reservoir bag through high-
pressure tubing. From the reservoir bag gas was directed to the
subject through a tube connected to a two way breathing valve
and mouthpiece [13]. Expired gases passed through a flow sensor
and ventilation was measured and recorded as verification of
respiration intensity (Vmax 22 Metabolic Measurement Cart,
SensorMedics, Yorba Linda, CA). EVH has a relatively high
sensitivity to identify EIB and a high negative-predictive value
[27].
Pulmonary Function Tests
Pulmonary function tests were conducted on all subjects using a
calibrated computerized pneumotachograph spirometer (Vmax
22, SensorMedics, Yorba Linda, CA) according to according to
American Thoracic Society (ATS) recommendations [28]. The
maximum percentage fall in FEV1 from the baseline (pre-EVH)
value was calculated using the following equation: (Pre-EVH
FEV1 – lowest post-EVH FEV1)/(Pre-EVH FEV1). In addition,
the bronchoconstrictor response to EVH was assessed as the area
under the curve of the percentage fall in post-EVH FEV1 plotted
against time for 20 min (AUC0–20), using trapezoidal integration.
Fraction of Exhaled Nitric Oxide
Fraction of exhaled nitric oxide (FENO) was measured with an
online measurement of resting values using a restricted exhaled
breath protocol (NOA 280i Nitric Oxide Analyzer, Accurate NO
Breath Kit, Thermal Mass Flowmeter, NO Analysis software
Version 3.21, Sievers Instruments, Boulder, CO). Measurements
were conducted as outlined by American Thoracic Society
guidelines [29]. Three exhalations were performed with nose clips
at each test with at least 30s between exhalations [29]. The
procedure entailed maximal inhalation to total lung capacity and
immediate exhalation against expiratory resistance for at least
6 sec to obtain a NO plateau lasting at least 3 sec. Subjects were
instructed to maintain a flow rate of 50610 mL/s as monitored by
a visual computer display.
Quantification of Exhaled Breath Condensate Markers
EBC samples were collected with a specially designed
condensing chamber (ECoScreen, Jaeger, Hoechberg, Germany)
using ATS/ERS recommendations [30]. The EBC protocol
required subjects to breathe normally, wearing nose clips, through
a mouthpiece connected to a non-rebreathing valve, whereby
exhaled breath entered a condenser system. A temperature of
220uC inside the condensing chamber, which was maintained
throughout the collection time, produced immediate sample
freezing. Exhaled breath was collected for 10 min prior to and
intervals (0–10min) following the EVH challenge.
The pH of the non-deaerated EBC was measured immediately
following collection (Orion 2 star pH meter, Thermo Scientific,
Beverly, MA). It has been shown that pH measurements in EBC
collected by ECoScreen are repeatable and reproducible [31].
The remainder of the condensate was stored at 280uC for later
analysis of Cyst-LTs using enzyme immunoassay techniques
(Cayman Chemicals, Ann Arbor, MI) as previously discussed
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related compounds was: LTC4 (100%), LTD4 (100%), LTE4
(67%), LTD5 (61%), LTC5 (54%), LTE5 (41%), N-acetyl-LTE4
(10.5%) and below 0.01% for other primary eicosanoid metabo-
lites. The intra- and inter-assay coefficient of variation (CV) for the
Cyst-LT enzyme immunoassay kit was ,10% respectively.
Urinary 9a,1 1 b- Prostaglandin (PG) F2 Quantification
Urine collection containers were provided to each subject during
each visit to the laboratory, and the urine was subsequently pipetted
into microfuge tubes and stored at 280uC until analysis. Urine was
assayed for 9a,11b-PGF2 using enzyme immunoassay techniques
(Cayman Chemicals, Ann Arbor, MI) as discussed previously [19].
The 9a,11b-PGF2 antibody cross-reacted with 2,3 dinor-11b-
PGF2a (10%), 11b-13,14-dihydro-15-keto-PGF2a (0.5%) and below
0.01%forall otherprimaryeicosanoidmetabolites.Inter-and intra-
assay CV for the 9a,11b-PGF2 assay were ,15%. The concentra-
tion of 9a,11b-PGF2 was adjusted for creatinine concentration
(Cayman Chemicals, Ann Arbor, MI). The intra- and inter assay
CV for creatinine was 2.7 and 3.0 respectively.
Nutrient Intake and Compliance
Nutrient intake was monitored to ensure that dietary factors that
could potentially affect asthma or EIB did not change through the
course of the study. Nutrient data was collected using the GSEL
food frequency questionnaire developed by the Nutrition Assess-
ment Shared Resource (NASR) of Fred Hutchinson Cancer
Research Center. This questionnaire has been shown to be valid
and reliable in the collection of dietary data [32]. Subjects
completed the GSEL version of the questionnaire at the first testing
session and at the end of each supplementation period. Analysis of
GSEL for nutrient intake was conducted by the Fred Hutchinson
Cancer Research Center. Nutrients of interest obtained from the
GSEL analysis included macronutrient composition, antioxi-
dants,(a-tocopherol, b-carotene, lycopene, Vitamin C), certain
minerals (magnesium, sodium, zinc), and types of dietary fatty
acids (omega-3, total polyunsaturated fatty acids, saturated fatty
acids). Adherence to the treatment regimen was monitored by
askingthe subjects to document the dose of capsulesconsumed daily
and to return anyunused capsules [33]. Forthe purpose ofthe study
a compliance of $90% was considered acceptable.
Symptoms, Rescue b-Agonist Use and Peak Flow
Measurements
Symptoms such as wheeze, shortness of breath, chest tightness,
and cough wererecordedbyeachsubject once dailywiththe useof a
logbook.Thesymptom severityrating scalewas definedas follows:0:
absent, no symptoms; 1: mild, symptom was minimally troublesome
(not sufficient to interfere with normal daily activity or sleep); 2:
moderate, symptom was sufficiently troublesome to interfere with
normal daily activity or sleep; 3: severe, symptom was so severe as to
prevent normal activity and/or sleep. All subjects were instructed to
record each use of their rescue medication throughout the study
duration,entering eachmedication useandthe numberof puffs used
per occasion. Subjects were asked to perform 3 peak flow maneuvers
at home in the morning and evening 2 weeks prior to the start of
study, and throughout the course of the study. The subjects were
provided with a peak flow meter (Piko-1, Ferraris, Louisville, CO)
and a log to record the best of 3 trials.
Data Analysis
The primary analysis was on an intention-to-treat basis and
involved all subjects who were randomly assigned. Data were
analyzed using the SPSS version 16.0 statistical software (SPSS
Inc., Chicago, USA). Normality of data was assessed using a
Kolmogorov–Smirnov test and Levene’s test was used to check for
homogeneity of variance between groups. A repeated measures
analysis of variance (ANOVA) was used to analyze the data
(within-subject) at baseline (n=10) and for the single (n=10) and
combination treatment (n=10). A Mauchly’s test was conducted
to determine if sphericity was violated. If sphericity was violated,
the repeated measures ANOVA was corrected using a Green-
house-Geisser adjustment factor. Pairwise comparisons, with a
Bonferroni adjustment (used to maintain an overall type-I error
rate of 5%), were used to isolate differences in group means:
dividing the probability value (0.05) by the number of pairwise
comparisons to be made. As a check, differences between baseline
(n=20) and the combination treatment (n=20) values were
compared using a paired t-test, while an unpaired t-test was used
to analyze differences between the two single treatment arms. The
Wilcoxon signed rank test was used to compare symptom scores
and bronchodilator use during the trial. Data are expressed as
mean 6 SD.
Results
Subjects
Bronchodilator use (average number of doses/puffs per day) was
significantly reduced (p,0.05) during the three treatment periods
(fish oil: 0.560.8; montelukast: 0.460.5; combination therapy (fish
oil plus montelukast): 0.360.6) compared to pre-treatment
(baseline) (0.660.9). No significant difference (p.0.017) in
bronchodilator use was observed between the three treatment
periods. No significant difference (p.0.05) was found between
pre-treatment (0.760.1) and following treatment with fish oil
(0.760.2), montelukast (0.660.2) and combination therapy
(0.660.1) for asthma symptoms scores. In addition, no significant
difference (p.0.017) was found for asthma symptom scores
between three treatments. No significant differences (p,0.017)
were found in morning or evening peak flow (morning:
403.2624.1 L/min, pre-supplementation; 379.8621.4 L/min,
montelukast; 357.8633.9 L/min, fish oil; and 382.2625.1 L/
min combination therapy) (evening: 418623.3 L/min, pre-
supplementation; 392.7617.3 L/min, montelukast; 368.36
34.9 L/min, fish oil; and 393.3627.6 L/min combination ther-
apy).
Pulmonary Function
No significant difference (p.0.017) was observed between
groups (pre-supplementation, fish oil, montelukast and combina-
tion treatment) in baseline (pre-EVH) pulmonary function
(Table 2). The percentage change in the pre- and post-treatment
drop in post-EVH FEV1 is shown in Figure 1. Prior to treatment
the maximum percent drop in post-EVH FEV1 was 218.462.1%.
However, there was a significant reduction (p,0.05) in post-EVH
FEV1 to 29.362.8% on fish oil, to 211.6+2.8%, on montelukast,
and to 210.861.7% on the combination treatment. There was no
significant difference (p.0.017) in the maximum percent drop in
post-EVH FEV1 between the three treatment groups. Similar
changes, as a result of treatment, were observed for the maximum
percent drop in post-EVH FEF25–75% (Figure 2) and FVC.
The bronchoconstrictor response to EVH, as determined by the
AUC0–20 for FEV1 was significantly greater (p,0.05) during pre-
treatment (2228.8633.3) compared post-treatment (fish oil,
2114.9635.5; montelukast, 2152.8654.4; combination treat-
ment, 2125.5620.6). No significant difference (p.0.017) between
the treatment groups was observed for post-EVH AUC0–20 for
Diet, Exercise and Asthma
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13487Figure 1. The percentage change in FEV1 from pre- to post- EVH for the usual diet (pre-treatment) and across the three treatments.
Reductions in post-EVH in excess of 10% represent abnormal pulmonary function. Letters a and b refer to comparisons by treatment within
respective time period. Different letters designate a significant difference (p,0.05).
doi:10.1371/journal.pone.0013487.g001
Figure 2. The percentage change in FEF25–75% from pre- to post- EVH for the usual diet (pre-treatment) and across the three
treatments. Letters a and b refer to comparisons by treatment within respective time period. Different letters designate a significant difference
(p,0.05).
doi:10.1371/journal.pone.0013487.g002
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EVH FEF25–75% and FVC.
Fraction of Exhaled Nitric Oxide
A significant difference (p,0.05) was observed in baseline (pre-
EVH) FENO between pre- treatment (42.566.6 ppb) and post-
treatment values (fish oil, 25.563.9 ppb; montelukast, 34.06
7.9 ppb; combination treatment, 23.263.4 ppb; Figure 3). How-
ever, no significant difference (p.0.017) was observed in baseline
FENO between the three treatments. In addition, there were no
significant differences (p.0.05) between the pre-treatment
(33.965.7 ppb) post-EVH FENO compared to post-treatment
values (fish oil, 23.165.0; montelukast, 35.068.3 ppb; combina-
tion treatment, 30.267.9).
Exhaled Breath Condensate and Urinary Inflammatory
Markers
The EBC pH was significantly lower (p,0.05) pre-supplemen-
tation (6.960.10) compared to all treatments (fish oil, 7.460.11;
montelukast, 7.360.07; combination treatment, 7.460.04). How-
ever, the pH of EBC did not differ significantly (p.0.017) between
any of the three treatments.
Mean EBC Cyst-LT levels for pre- and post-EVH before and
after treatment are shown in Figure 4. Fish oil, montelukast and
the combination treatment resulted in a significant reduction
(p,0.05) in pre-EVH EBC Cyst-LT concentration of 43.062.8%,
33.262.6% and 34.562.3% respectively compared to the pre-
EVH Cyst-LT baseline concentration. Likewise, the fish oil,
montelukast and combination treatment significantly reduced
(p,0.05) the post-EVH EBC Cyst-LT concentration by
41.863.4%, 38.063.9% and 42.862.8% compared to the pre-
treatment post-EVH Cyst-LT concentration.
Mean urinary 9a,1 1 b PGF2 levels for pre- and post-EVH
before and after treatment are shown in Figure 5. The fish oil and
the combination treatment resulted in a significant reduction
(p,0.05) in pre-EVH urinary 9a,1 1 b PGF2 concentration of
34.062.7% and 48.163.4% respectively compared to the pre-
EVH urinary 9a,1 1 b PGF2 pre-treatment concentration. No
significant difference (p.0.05) was observed between pre-treat-
ment and montelukast treatment for the pre-EVH urinary 9a,1 1 b
PGF2 concentration.
The fish oil and combination treatment significantly reduced
(p,0.05) the post-EVH urinary 9a,1 1 b PGF2 concentration by
17.162.2% and 17.862.5% compared to the post-EVH urinary
9a,1 1 b PGF2 pre-treatment concentration. However, no
significant difference (p.0.05) was observed between pre-treat-
ment and montelukast for the post-EVH urinary 9a,1 1 b PGF2
concentration.
Nutrient Intake and Compliance
Subject adherence to the treatment regimens were assured by
finding that pill counts at the end of each supplement period
reflected that capsules were consumed regularly. Compliance as
estimated from return-tablet count was high (median, 98%).
Though usual diet was expected to vary between and among
subjects, mean daily nutrient intake of the subject’s diets did not
differ significantly between the treatment regimens (p.0.05).
(Table 3).
Discussion
This study has shown that fish oil and montelukast were both
effective in reducing the airway reactivity to hyperpnea with dry
air, however when fish oil was combined with montelukast no
further attenuation in airway inflammation or hyperpnea-induced
bronchoconstriction was observed. All three treatments signifi-
cantly reduced bronchodilator use and improved post-exercise
pulmonary function as demonstrated by the reduction in post-
EVH FEV1 and FEF25–75%, and reduced the severity of
hyperpnea-induced bronchoconstriction as measured by AUC0–
20. Fish oil, montelukast and the combination treatment
significantly reduced the fall in FEV1 post-EVH by approximately
49%, 37% and 41% respectively. We have previously shown that 3
Figure 3. Mean fraction of exhaled nitric oxide (FENO) concentration (ppb). Different letters designate a significant difference (p,0.05)
between treatments pre-EVH.
doi:10.1371/journal.pone.0013487.g003
Diet, Exercise and Asthma
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13487weeks of fish oil supplementation (3.2 EPA and 2.0g DHA per day)
reduced the fall in FEV1 at 15 minutes post-exercise by almost
80% in elite athletes with EIB [19], and reduced the post-exercise
fall in FEV1 by approximately 64% in asthmatic subjects with EIB
[18]. The degree of protection provided by montelukast on
hyperpnea-induced bronchoconstriction in the present study is
similar in magnitude to previous reports using an exercise
challenge [11,12], which have shown that 2-hr following a single
10-mg dose of montelukast the maximum fall in post-exercise
FEV1 was reduced by approximately 52% [11] and 33% [12]
compared to placebo treatment. In the present study symptom
scores did not change as result of treatment. This is not
unexpected since it is well documented that symptoms have poor
predictive value for the diagnosis of EIB [34,35].
It has been shown that airway pH is an important determinant
of expired FENO and airway inflammation, and thus there may be
a casual relationship between airway acidification and airflow
limitation in asthma [36]. EBC pH is lower in asthmatics and
correlates positively with sputum eosinophilia, total nitrate/nitrite
and oxidative stress, and shows good repeatability in asthmatics
Figure 4. Mean exhaled breathe condensate (EBC) cysteinyl-leukotriene concentration (pg.mg
21). * designates a significant difference
compared to pre-treatment (usual diet) pre-EVH. # designates a significant difference compared to pre-treatment (usual diet) post-EVH.
doi:10.1371/journal.pone.0013487.g004
Figure 5. Mean urinary 9a,1 1 b-prostaglandin F2 concentration (ng.mg mmol creatinine
21). * designates a significant difference
compared to pre-treatment (usual diet) pre-EVH. # designates a significant difference compared to pre-treatment (usual diet) post-EVH.
doi:10.1371/journal.pone.0013487.g005
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acidity both accelerates human eosinophils necrosis and can cause
the conversion of endogenous nitrate (NO2
2) to nitric oxide (NO)
and importantly, the acidic airway breath condensate pH in
asthma normalizes with anti-inflammatory therapy [36], which
supports our observation that all three anti-inflammatory treat-
ments (fish oil, montelukast and combination treatment) signifi-
cantly raised EBC pH compared to the more acidic pre-treatment
value.
In the present study fish oil, montelukast and the combination
treatment all reduced the pre-hyperpnea FENO compared to the
pre-treatment value in the EIB subjects, suggesting amelioration in
baseline airway inflammation. Previous studies have shown that
FENO can be used as an indirect marker of asthmatic airway
inflammation [38], and have shown a relationship between FENO
levels and EIB [39,40,41]. It has been shown that montelukast
reduces FENO in patients with mild and chronic asthma
[38,42,43], suggesting an anti-inflammatory role for Cyst-LT1
receptor antagonism in asthma. Likewise, supplementation with
omega-3 polyunsaturated fatty acids has been shown to reduce
FENO in patients with atopic asthma [44].
Eicosapentaenoic acid and DHA, derived from fish oil, can
cause dual inhibition COX-2 and 5-LO pathways for metabolism
of arachidonic acid. It has been shown that 5-LO product
formation in the lung capillary bed is critically dependent on
intravascular precursor fatty acid supply, with EPA representing
the preferred substrate compared with arachidonic acid [45].
Eicosapentaenoic acid can inhibit release of arachidonic acid
derived eicosanoids, thus reducing the generation of pro-
inflammatory ‘tetraene’ 4-series LTs and 2-series prostanoids,
and production of cytokines from inflammatory cells [46], and
increasing the 5-series LTs [45]. Eosinophils, mast cells, basophils,
and alveolar macrophages can directly synthesize the 4-series
Cyst-LTs, which can increase vascular permeability and contract
smooth muscle cells, causing bronchoconstriction, and may
directly increase eosinophilic airway inflammation [18]. Although
DHA may have similar anti-inflammatory effects as EPA, it does
not act by direct competition with AA. DHA can decrease the
release of AA from membrane phospholipids by decreasing
phospholipase A2 activity [47], and decreasing the responsiveness
of toll-like receptor-4 to LPS, thereby suppressing nuclear factor-
kappaB activation and subsequent inflammatory gene transcrip-
tion [48].
We recently examined the effects of pure EPA and pure DHA,
and a variety of heterogeneous blends of EPA and DHA, on
eicosanoid (i.e., leukotrienes and prostaglandins) and cytokine
generation, and mRNA expression from LPS-stimulated human
asthmatic alveolar macrophage cells [49]. The data indicate that
the greater the EPA content of a fish oil formulation the greater
the eicosanoid and cytokine reduction. In addition, a new class of
mediator families derived from fish oil—the EPA- and DHA-
derived resolvins (RvE1 and RvD1) and the DHA-derived
protectin (PD1), which act locally, and possess potent anti-
inflammatory novel bioactions have recently been indentified
and may represent a potential mechanism for the therapeutic
benefits derived from diets rich in these omega-3 essential fatty
acids.
We have previously shown in elite athletes with EIB [19] that 3
weeks of fish oil supplementation (3.2 g EPA and 2.0 g DHA per
day) increased tissue phospholipid n-3 PUFA concentration
coincident with a significant suppression of urinary and blood
eicosanoids (LTE4,9 a,1 1 b-PGF2, and LTB4, respectively) and
pro-inflammatory cytokines (TNF-a and IL-1b). In a follow-up
study [18] we found that sputum differential eosinophil,
neutrophil, lymphocyte and macrophage cell counts and sputum
supernatant concentrations of pro-inflammatory eicosanoids
(LTC4-LTE4 and PGD2), and cytokines (TNF-a, IL-1b) were
significantly reduced on a 3 week fish oil diet in asthmatic subjects
with EIB. In addition, the amount of LTB5, a weak and partial
antagonist compared with LTB4 in eliciting chemotactic and
aggregating responses, generated from activated polymorphonu-
clear leukocytes was markedly increased following fish oil
supplementation. The data from the present study and our
previous observations [18,19,49] strongly suggest that dietary
supplementation with fish oil can suppress airway inflammation in
asthmatic subjects with EIB.
Table 3. Mean daily nutrient intake for each treatment period.
Baseline (Pre-Treatment)* Montelukast Fish Oil Combination Treatment
Alphatocopherol (mg) 10.461.5 9.762.2 8.961.9 9.161.3
Beta Carotene (mg) 44806799 490061294 31966523 430961063
Lycopene (mg) 989961726 778162167 811062710 774161147
Vitamin C (mg) 136.0614.9 130.6617.0 99.2611.3 102610.3
Magnesium (mg) 389.0643.0 350668.0 343659.0 341635.0
Sodium (mg) 38546478 32396605 36006786 32116367
Zinc (mg) 12.161.3 12.162.3 12.962.5 13.961.8
Monounsaturated Fatty Acids (g) 29.964.1 26.165.2 28.366.3 25.563.1
Omega-3 Fatty Acids (g) 1.560.2 1.460.2 1.360.3 1.360.2
Polyunsaturated Fatty Acids 16.562.1 14.862.7 15.163.2 13.861.8
Saturated Fatty Acids (g) 27.163.6 24.064.8 26.265.9 23.662.9
Protein (g) 96.1612.6 83.2614.9 91.9621.4 80.868.1
Carbohydrates (g) 299.1628.8 253.8648.8 275.8648.4 253.6624.7
Fat (g) 79.7610.3 70.7613.6 75.6616.3 68.268.2
Values are mean 6 SEM. There were no significant differences (p.0.05) between groups for any specific nutrient.
*Food frequency measured from each subject on their usual diet.
doi:10.1371/journal.pone.0013487.t003
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treatment significantly reduced EBC Cyst-LT concentrations.
Studies have shown a sustained increase in Cyst-LTs and other
bronchoconstrictve eicosanoids, such as PGD2, in the airways after
an exercise challenge [4,50], and have been shown to be elevated
for up to 6 hours after an exercise challenge in asthmatic subjects
with EIB [4,50]. Eosinophils, mast cells and basophils can directly
synthesis Cyst-LTs, which can cause tissue edema, stimulate
airway secretions, promote cell cycling and proliferation of airway
smooth muscle, and may directly increase eosinophilic inflamma-
tion [24]. It has been shown that in some patient populations, the
amount of eosinophilia in induced sputum is correlated with EIB
severity [51]. Hallstrand et al. [52] have found that following an
exercise challenge there was an increase in secreted phospholipase
A2 group X (sPLA2 –X) protein in induced sputum and the
percentage of epithelial cells immunostaining for sPLA2 –X in
asthmatics with EIB. These findings [52] may provide an
explanation for the elevated levels of pre-treatment EBC Cyst-
LTs observed in the present study.
The inhibition of EIB by a Cyst-LT1 receptor antagonist alone
is incomplete, which implicates other bronchoconstrictve media-
tors in the pathogenesis of EIB [53]. In the present study fish oil
and the combination treatment, but not montelukast, significantly
blunted the increase of 9a,1 1 b-PGF2 in urine following the dry
gas hyperpnea challenge. In humans, PGD2 is a potent
bronchoconstrictor [54] that is almost exclusively produced by
mast cells [55]. 9a,1 1 b-PGF2, the urinary metabolite of PGD2,
has been shown to be increased after allergen-induced broncho-
constriction [56], EIB [57], mannitol-induced bronchoconstriction
[58] and hyperpnea-induced bronchoconstriction [25].
Since montelukast only blocks the bronchoconstrictor response
to exercise by up to 70% [9,10,11,12,13,14] it is perhaps surprising
that both fish oil and montelukast had similar effects on the
magnitude of attenuation of EIB and airway inflammation. A
possible explanation for the apparently similar anti-inflammatory
and bronchoconstrictor effects of fish oil and montelukast may be
related to the dose and/or omega-3 fatty acid content of fish oil
used in the current study. It is possible that a different
concentration of EPA/DHA or a higher dose of fish oil may
cause a greater suppression of EIB and airway inflammation; we
have previously shown that the greater the EPA content of a fish
oil formulation the greater the inhibition of the inflammatory
response in human asthmatic alveolar macrophage cells [49].
However, the optimal daily intake and formulation of fish oil to be
used to suppress EIB and airway hyperresponsiveness in asthma
has not yet been determined.
Although both fish oil and montelukast alone significantly
attenuated airway inflammation and hyperpnea-induced bron-
choconstriction, treatment with fish oil and montelukast in
combination did not provide a greater anti-inflammatory effect
and suppression of bronchoconstriction than either treatment
alone. A possible explanation for this observation may relate to the
fact that fish oil feeding results in a decreased capacity of
inflammatory cells to synthesize COX-2 and 5-LO-derived
eicosanoids from arachidonic acid [59], which includes blocking
the generation of Cyst-LTs from resident airway cells [18,19],
while montelukast, which is working further down the eicosanoid
metabolic pathway, only blocks the receptor that binds the
Cyst-LTs.
The present study has several limitations. First, the absence of a
non-active treatment arm (double-dummy) in the study design,
and the absence of statistical power for equivalence testing
between fish oil supplementation and montelukast, is a weakness
that should be acknowledged. Second, the included patients were
asthmatic with documented HIB and therefore the conclusions
drawn from this small proof-of-concept study should not be
generalized to all individuals with asthma.
In conclusion, while we have demonstrated that fish oil and
montelukast are both effective in attenuating airway inflammation
and hyperpnea-induced bronchoconstriction in asthmatic subjects,
treatment with fish oil and montelukast in combination does not
provide a greater anti-inflammatory effect or suppression of
bronchoconstriction than either treatment alone. It is clear that
fish oil supplementation should be considered as an alternative
treatment for EIB. Importantly, fish oil, rich in EPA and DHA,
holds promise for providing relief from pathologic airway
responses by serving as pro-resolving agonists and/or inflamma-
tory antagonists in stimulating a return to respiratory homeostasis
in asthma and EIB.
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